Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
APRINOIA Therapeutics, LLC
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05344989CT.gov A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Tauopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apnmab005 (this asset) | APRINOIA Therapeutics, LLC | P1 | CC · 43 |
| Flortaucipir | Columbia University | P2 | BB |
| Donanemab | Eli Lilly and Company | P3 | B |
| NA 831 | Biomed Industries, Inc. | P2 | B |
| Jaci-35.054 | AC Immune SA | P1/2 | CCC |
| Aci-35.030 | AC Immune SA | P1/2 | CCC |
| Pegipanermin | Inmune Bio, Inc. | P2 | CCC |
| Davunetide | University of California, San Francisco | P1 | CC |
| Gosuranemab | University of California, San Francisco | P1 | CC |
+6 more in the Tauopathy cohort
Other indications for Apnmab005
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apnmab005 in Tauopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apnmab005-tauopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →